Breast cancer is the most commonly diagnosed cancer in the UK, with more than 45,000 new cases per year, and a lifetime risk of 1 in 9 [1]. Incidence rates have risen over the past 20 years in industrialised countries, but the same period has seen the development of many new treatments, and eight out of ten women diagnosed with breast cancer are now expected to survive 5 years or more [1, 2] . Th e improvements in treatment include novel cytotoxic drugs and many targeted agents, such as trastuzumab, lapatinib and the aromatase inhibitors.
Introduction
Breast cancer is the most commonly diagnosed cancer in the UK, with more than 45,000 new cases per year, and a lifetime risk of 1 in 9 [1] . Incidence rates have risen over the past 20 years in industrialised countries, but the same period has seen the development of many new treatments, and eight out of ten women diagnosed with breast cancer are now expected to survive 5 years or more [1, 2] . Th e improvements in treatment include novel cytotoxic drugs and many targeted agents, such as trastuzumab, lapatinib and the aromatase inhibitors.
Within the past 5 years, it has become apparent that another powerful class of agents -the poly(ADP-ribose) polymerase (PARP) inhibitors -has activity in defi ned groups of patients with breast cancer [3] [4] [5] [6] [7] [8] [9] [10] [11] . Th ese agents target a DNA repair pathway via a novel mechanism of action that can be exploited to the benefi t of patients with breast cancer. Th is review will briefl y discuss the development of PARP inhibitors, and the data supporting their potential clinical use in breast cancer, as single agents and in combination with chemotherapy.
cell kill [19] . For this reason, PARP inhibitors were fi rst developed as radio-or chemo-potentiating agents [20, 21] , the aim being to overcome cancer cell resistance to a DNA-damaging agent by preventing repair of the potentially lethal damage to the cancer cell caused by the treatment.
Potent PARP inhibitors fi rst entered early clinical trials in 2003 [22] , and there has been rapid expansion of the fi eld in the past 5 years. Several PARP inhibitors are being investigated for a range of indications [23, 24] , mainly cancers (Table 1) . Early clinical studies suggest that PARP inhibitors will have a role in the treatment of breast cancer, with promising data emerging from trials in two specifi c areas: hereditary BRCA-defi cient breast cancer (single-agent PARP inhibition) and triple-negative breast cancer (TNBC; PARP inhibition in combination with chemotherapy) [3] [4] [5] [6] [7] [8] [9] [10] [11] . However, with improved understanding of the mechanisms of PARP1 inhibition in these two clinical scenarios, it is likely that a wider group of patients with breast cancer may also benefi t from this approach to treatment.
Single-agent PARP inhibitors in hereditary BRCAdefi cient cancer
Th e publication in 2005 of paired pre-clinical papers in Nature, demonstrating hypersensitivity of BRCA-deficient cancer cells to single-agent PARP inhibitors, opened the door to clinical research into these agents as monotherapy [25, 26] , and provided the clearest demonstration to date of a class eff ect. Before this ground-breaking research was published, it had been argued that PARP inhibitors would have no activity when used alone, and drug developers were chasing the elusive goal of chemopotentiation in tumours without an increase in toxicity in normal tissue.
Initial preclinical experiments in cell lines and xenografts demonstrated that cells with loss of the homolo gous recombination repair pathway for DNA double-strand breaks (DSBs) are hypersensitive to blockade of SSB repair with a PARP inhibitor. Th e key to this mechanism of action is the role that BRCA1 and BRCA2 play in signalling DSBs (BRCA1) and the repair of such breaks via the homologous recombination pathway (BRCA2) [27] .
Th e proposed mechanism for the cytotoxicity of PARP inhibition is that blockade of SSB repair leads to the formation of unrepaired DSBs at the replication fork. In normal or BRCA-heterozygous cells, the lesion can be repaired by DSB mechanisms, and DNA replication and cell division continue. However, in cells that lack functional DSB repair, such as those with a homozygous mutation in BRCA1 or BRCA2, loss of two DNA repair pathways causes synthetic lethality and cell death [25, 26] .
Th is proposition was fi rst tested clinically in a phase I study of AZD2281 (olaparib), looking at its potential activity as a single agent [28] . Th is study used an oral formulation of olaparib, and assessed the pharmacokinetics and pharmacodynamics of doses ranging from 10 mg daily for 2 out of 3 weeks to 600 mg twice daily on a continuous schedule. Nine of the 19 patients with confi rmed BRCA mutations had a partial response to olaparib, representing a 47% response rate in this population. No responses were seen in 37 patients who did not have a BRCA mutation. Th e dose-limiting toxicities were myelosuppression and central nervous system side eff ects. Toxicities to normal tissue were similar in the BRCA-defi cient and normal populations. An increase in γH2AX foci was found in plucked eyebrow hair follicles 6 hours after olaparib treatment, compared with baseline. Th ese foci indicate accumulation of DNA DSBs, so the fi nding demonstrated a proof of mechanism of the process of synthetic lethality, whereby preservation of SSBs by PARP inhibition leads to the formation of DNA DSBs in the absence of an external DNA-damaging agent. It must be noted, however, that the mechanistic proof was demonstrated in normal tissue, not in the tumour. It is not clear from the publication whether this pharmacodynamic eff ect was seen in BRCA carriers with a heterozygote defect in all cells, or in all patient groups. Th ese data, which suggest a risk of accumulation of DNA damage within normal tissue, raise concern over the potential dangers of prolonged, continuous dosing. In theory, there could also be an accumulation of tumourigenic mutations and second malignancies, so caution in the use of these agents in the adjuvant setting over prolonged periods may be advisable.
Th e phase I fi ndings have been confi rmed by two phase II studies of olaparib in BRCA1 or BRCA2 mutation carriers in patients with breast [3, 4] or ovarian [5, 6] cancer previously treated with a median of three chemotherapy regimens. Both studies assessed response and toxicity in sequential cohorts of patients treated with 400 mg twice daily or 100 mg twice daily. Th e activity of olaparib as a single agent was confi rmed in the 400 mg cohorts, but there was less activity at the lower dose, suggesting that the extent of PARP inhibition is important for response. In the breast cancer study, 27 patients with metastatic disease were treated at each dose, and the confi rmed response rate was 41% in those receiving the 400 mg schedule and 22% in the 100 mg cohort [3, 4] . Toxicity was reduced with the lower dose, compared with the higher dose, but mild overall. Fatigue, nausea and vomiting were the commonest adverse events with this well tolerated agent.
A similar dose response was found in the phase II study of ovarian cancer, in which 33 patients were treated with olaparib 400 mg twice daily and 24 with 100 mg twice daily. Th ere was a 33% confi rmed partial response rate at the higher dose and 13% at the lower dose [5, 6] . Responses were seen in carriers of BRCA1 or BRCA2 muta tions, and in patients with either platinum-sensitive or platinum-resistant disease. However, these results are not consistent with fi ndings from previous studies that acquired resistance to platinum-based treatment in ovarian cancer is associated with regain of BRCA function [29, 30] .
Th e fi ndings of these small, non-randomised phase I and phase II studies require confi rmation at phase III. Meanwhile, they do provide the exciting suggestion that single-agent therapy with PARP inhibitors will be of benefi t in BRCA-positive patients, and off er low toxicity. Phase II studies in this indication are ongoing with the PARP inhibitors PF01367338 (AG014699) and ABT-888 (veliparib). A phase I single-agent study with the novel PARP inhibitor MK-4827 has also confi rmed the potential for activity with low toxicity in this group of patients [31] .
PARP inhibitors as chemo-potentiating agents
As discussed above, PARP inhibitors were initially envisaged as chemo-potentiating agents. In previous studies, using inhibitors of methyl guanine methyl transferase to prevent DNA repair during cytotoxic therapy, the dose of chemotherapy needed to be reduced because of enhanced toxicity with the treatment combination [32] [33] [34] . Similarly, in some of the fi rst studies of PARP inhibitors in combination with chemotherapy, a higher level of myelosuppression was observed than would have been expected with the chemotherapeutic agent alone [7, 22, [35] [36] [37] . Two further studies required protocol amendments in light of dose-limiting toxicities associated with olaparib in combination with chemotherapy -in particular, myelosuppression [8, 38] . Th ese fi ndings present two challenges to physicians and scientists designing trials with combinations of chemotherapy with PARP inhibitors. First, should clinical studies be designed with the maximum dose of chemotherapy possible, or a maximal dose of PARP inhibitor accepting a chemotherapy dose reduction? Th e answer to this will lie in the clinical outcome data and also how the PARP inhibitor is being used -for its single agent activity or as a true chemo-potentiating agent. Second, there is a need to investigate the mechanism by which PARP inhibitors enhance damage to normal tissue when used with some of the agents reported (platinums, bifunctional alkylating agents such as cyclophosphamide or the antimetabolite, gemcitabine), where repair of cytotoxic damage is not thought to be achieved via a PARP-dependent mechanism. Th ere is one molecule in the class -BSI-201 (SAR 240550, iniparib) -for which normal tissue toxicity appears to be less of an issue, and so far this is the PARP inhibitor that has progressed furthest in the clinic.
PARP inhibitors in triple-negative breast cancer
Following encouraging results with iniparib in combination with chemotherapy with various solid tumours [39] , clinical investigators have gone on to study this agent with chemotherapy in TNBC, a disease with a bio logical phenotype similar to BRCA1-defective cancers [40] . It must be borne in mind that iniparib may act via a diff erent mechanism to the PARP inhibitors discussed above, and does not appear to have the limitation of enhanced toxicity in normal tissue [39, 41, 42] . Evidence of an improvement in anti-tumour activity has been reported in patients previously treated with two or more cytotoxic regimens who received iniparib in combi nation with carboplatin and gemcitabine, compared with those who received the chemotherapy regimen alone [9] . In this phase II study, 123 patients with TNBC were randomised to receive carboplatin (AUC2) and gemcitabine (1,000 mg/m 2 ) on days 1 and 8 of a 21-day cycle, with or without iniparib 5.6 mg/kg on days 1, 4, 8 and 11. Th e objective response rate was 52% in the iniparib group, compared with 32% in those who received chemotherapy alone (P = 0.02), median progression-free survival was 5.9 versus 3.6 months, respectively (P = 0.01), and overall survival was 12.3 versus 7.7 months, respectively (P = 0.01) [9, 10] . No diff er ence was observed in the rate of adverse events between the two treatment groups. A phase III study of iniparib in combination with carboplatin and gemcitabine for the same indication was initiated in 2009, and rapidly completed recruitment. It is hoped that preliminary results will be reported at the American Society of Clinical Oncology (ASCO) 2011 meeting. However, initial indications from the manufacturer, Sanofi -Aventis, are that the phase III trial did not meet the primary endpoints of overall and progression-free survival [43] .
It is possible that the intermittent dosing regimen used in the studies cited above helps to protect against enhanced myelosuppression and hence toxicity. However, if iniparib is acting as a PARP inhibitor, it is intriguing that this intermittent schedule also provides an increase in overall treatment effi cacy, compared with chemotherapy alone. It is possible that iniparib is acting as a single agent on the BRCA-like phenotype of TNBC, or that it is somehow able to prevent repair to treatmentinduced DNA damage within the tumour without increased damage to normal tissue. If they confi rm the phase II data, the results of the phase III study of iniparib and chemotherapy in TNBC may lead to an advance in the treatment of patients, but they will also present an intriguing puzzle to scientists working with PARP inhibitors.
It is also interesting to note that single-agent olaparib was described as having activity in TNBC at the ASCO 2010 meeting [11] . Th is was the fi rst trial to evaluate the effi cacy of a PARP inhibitor as a single agent for the treatment of sporadic TNBC, and responses were seen only in tumours that occurred on a background of BRCA1 germline mutation [11] .
Conclusion
Research into PARP inhibition is beginning to show the potential of targeting DNA repair as a strategy in the development of new anti-cancer agents. Th is is a class of drugs with activity as monotherapy and in combination with treatments that cause DNA damage [4, 8, 38] . It is very unusual in cancer therapy for a new drug to be used solely as monotherapy, and research to date suggests that PARP inhibitors are likely to be used also as components of combination regimens. Indeed, the single-agent and DNA-damaging-potentiating facets of PARP inhibition present an interesting challenge to drug developers as we try to improve treatments for our patients. If we wish to exploit the single-agent activity of a PARP inhibitor as part of a combination regimen, we may need to consider scheduling PARP-based treatment separately to any DNA-damaging component of the combination. However, when using a PARP inhibitor as a chemopotentiator, concomitant treatment would be appropriate.
Th e phase III trial of iniparib in TNBC is nearing completion. If the data confi rm the earlier fi ndings, it will provide a promising new treatment for this patient group. However, there remain many scientifi c questions about the underlying mechanism of action of iniparib in this setting, and the diff erences between the individual agents in the PARP inhibitor class.
Whatever the explanation, PARP inhibition may eventually off er an eff ective treatment approach for patients with BRCA-related breast cancer and TNBC, and the array of compounds in development will allow clinical investigators to exploit the diff erences to extend our scientifi c knowledge and thus benefi t a wider range of patients.
